A new study has calculated the average cost per case of TB in the EU. The findings suggest the economic burden of TB far outweighs the costs of investing in more effective vaccines.
The research, published online today (16 August 2013), in the European Respiratory Journal, is the first study to estimate the costs of the disease in recent years.
Researchers used a systematic review of literature and institutional websites for the 27 EU member states to summarise economic data on the treatment cost of TB cases in 2011.